Posted by Michael Wonder on 30 Jun 2018
Price of breast cancer drug ribociclib cut after being placed on Pharmaceutical Benefits Scheme
30 June 2018 - The breast cancer drug ribociclib has been placed on the Pharmaceutical Benefits Scheme, taking the price from $5000 a month to less than $500.
A medication that has cost breast cancer sufferers more than $70,000 a year will have its costs slashed to between $39.50 and $6.40 per script after being placed on the Pharmaceutical Benefits Scheme.
More than 3000 Australian patients with inoperable or metastatic hormone receptor positive breast cancer will benefit from the listing of ribociclib (Kisqali).
